Effect of highly active antiretroviral therapy on survival of HIV infected patients with non-small-cell lung cancer

Lung Cancer

Volumn 65, Issue 3, 2009, Pages 345-350

  Lavolé, Armelle ^a   Chouaïd, Christos ^b   Baudrin, Laurence ^c   Wislez, Marie ^a   Raguin, Gilles ^b   Pialoux, Gilles ^a   Girard, Pierre Marie ^b   Milleron, Bernard ^a   Cadranel, Jacques ^a  

^a HÔPITAL TENON   (France)

^b HÔPITAL SAINT ANTOINE   (France)

^c HÔpital Bichat   (France)

Author keywords

Adenocarcinoma; Highly active antiretroviral therapy; Human Immunodeficiency Virus Infection; Lung Cancer; Non Small Cell Lung Cancer; performans Status

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; CARBOPLATIN; CISPLATIN; DIDANOSINE; EMTRICITABINE; LAMIVUDINE; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ADULT; AGED; ARTICLE; ASIAN; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CAUCASIAN; CIGARETTE SMOKING; CONTROLLED STUDY; DEATH; ESOPHAGITIS; FEMALE; FOLLOW UP; FRANCE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LUNG LOBECTOMY; LUNG NON SMALL CELL CANCER; LUNG RESECTION; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NEGRO; OVERALL SURVIVAL; PNEUMONIA; PRIORITY JOURNAL; PROGNOSIS; RACE DIFFERENCE; UNIVERSITY HOSPITAL; WEIGHT REDUCTION;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE PROGRESSION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; SURVIVAL ANALYSIS; VIRUS REPLICATION;

EID: 67849124731     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2008.11.018     Document Type: Article

References (43)

1. Louie J.K., Hsu L.C., and Osmond D.H. Trends in causes of death among persons with acquired immunodeficiency syndrome in the era of highly active antiretroviral therapy, San Francisco, 1994-1998. J Infect Dis 186 (2002) 1023-1027
2. Mocroft A., Brettle R., and Kirk O. Changes in the cause of death among HIV positive subjects across Europe: results from the EuroSIDA study. AIDS 16 (2002) 1663-1671
3. Engels E.A. Human immunodeficiency virus infection, aging, and cancer. J Clin Epidemiol 54 Suppl. (1) (2001) S29-34
4. Bonnet F., Lewden C., and May T. Malignancy-related causes of death in human immunodeficiency virus-infected patients in the era of highly active antiretroviral therapy. Cancer 101 (2004) 317-324
5. Engels E.A., Pfeiffer R.M., Goedert J.J., Virgo P., McNeel T.S., Scoppa S.M., et al. Trends in cancer risk among people with AIDS in the United States 1980-2002. AIDS 20 (2006) 1645-1654
6. Herida M., Mary-Krause M., and Kaphan R. Incidence of non-AIDS-defining cancers before and during the highly active antiretroviral therapy era in a cohort of human immunodeficiency virus-infected patients. J Clin Oncol 21 (2003) 3447-3453
7. Cadranel J., Garfield D., and Lavole A. Lung cancer in HIV infected patients: facts, questions and challenges. Thorax 61 (2006) 1000-1008
8. Lavole A., Wislez M., and Antoine M. Lung cancer, a new challenge in the HIV-infected population. Lung Cancer 51 (2006) 1-11
9. Chaturvedi A.K., Pfeiffer R.M., and Chang L. Elevated risk of lung cancer among people with AIDS. AIDS 21 (2007) 207-213
10. Engels E.A., Brock M.V., and Chen J. Elevated incidence of lung cancer among HIV-infected individuals. J Clin Oncol 24 (2006) 1383-1388
11. Parker M.S., Leveno D.M., Campbell T.J., Worrell J.A., and Carozza S.E. AIDS-related bronchogenic carcinoma: fact or fiction?. Chest 113 (1998) 154-161
12. Alshafie M.T., Donaldson B., and Oluwole S.F. Human immunodeficiency virus and lung cancer. Br J Surg 84 (1997) 1068-1071
13. Brock M.V., Hooker C.M., and Engels E.A. Delayed diagnosis and elevated mortality in an urban population with HIV and lung cancer: implications for patient care. J Acquir Immune Defic Syndr 43 (2006) 47-55
14. Karp J., Profeta G., and Marantz P.R. Lung cancer in patients with immunodeficiency syndrome. Chest 103 (1993) 410-413
15. Sridhar K.S., Flores M.R., and Raub Jr. W.A. Lung cancer in patients with human immunodeficiency virus infection compared with historic control subjects. Chest 102 (1992) 1704-1708
16. Tirelli U., Spina M., and Sandri S. Lung carcinoma in 36 patients with human immunodeficiency virus infection. The Italian Cooperative Group on AIDS and Tumors. Cancer 88 (2000) 563-569
17. Vyzula R., and Remick S.C. Lung cancer in patients with HIV-infection. Lung Cancer 15 (1996) 325-339
18. Powles T., Nelson M., and Bower M. HIV-related lung cancer-a growing concern?. Int J STD AIDS 14 (2003) 647-651
19. Powles T., Thirwell C., Newsom-Davis T., Nelson M., Shah P., Cox S., et al. Does HIV adversely influence the outcome in advanced non-small-cell lung cancer in the era of HAART?. Br J Cancer 89 (2003) 457-459
20. Holkova B., Takeshita K., Cheng D.M., Volm M., Wasserheit C., Demopoulos R., et al. Effect of highly active antiretroviral therapy on survival in patients with AIDS-associated pulmonary Kaposi's sarcoma treated with chemotherapy. J Clin Oncol 19 (2001) 3848-3851
21. Tam H.K., Zhang Z.-F., Jacobson L.P., Margolick J.B., Chmiel J.S., Rinaldo C., et al. Effect of highly active antiretroviral therapy on survival among HIV-infected men with Kaposi sarcoma or non-Hodgkin lymphoma. Int J Cancer 98 (2002) 916-922
22. Navarro J.-T., Ribera J.-M., Oriol A., Vaquero M., Romeu J., Batlle M., et al. Influence of highly active anti-retroviral therapy on response to treatment and survival in patients with acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma treated with cyclophosphamide, hydroxydoxorubicin, vincristine and prednisone. Br J Haematol 112 (2001) 909-915
23. Newell M.E., Hoy J.F., Cooper S.G., DeGraaff B., Grulich A.E., Bryant M., et al. Human immunodeficiency virus-related primary central nervous system lymphoma: factors influencing survival in 111 patients. Cancer 100 (2004) 2627-2636
24. Vaccher E., Spina M., di Gennaro G., Talamini R., Nasti G., Schioppa O., et al. Concomitant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma. Cancer 91 (2001) 155-163
25. Weiss R., Mitrou P., Arasteh K., Schuermann D., Hentrich M., Duehrsen U., et al. Acquired immunodeficiency syndrome-related lymphoma: simultaneous treatment with combined cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy and highly active antiretroviral therapy is safe and improves survival-results of the German multicenter trial. Cancer 106 (2006) 1560-1568
26. Evison J., Jost J., Ledergerber B., Jost L., Strasser F., and Weber R. HIV-associated non-Hodgkin's lymphoma: highly active antiretroviral therapy improves remission rate of chemotherapy. AIDS 13 (1999) 732-734
27. Antinori A., Cingolani A., Alba L., Ammassari A., Serraino D., Ciancio B.C., et al. Better response to chemotherapy and prolonged survival in AIDS-related lymphomas responding to highly active antiretroviral therapy. AIDS 15 (2001) 1483-1491
28. Little R.F., Pittaluga S., Grant N., Steinberg S.M., Kavlick M.F., Mitsuya H., et al. Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology. Blood 101 (2003) 4653-4659
29. Ratner L., Lee J., and Tang S. Chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma in combination with highly active antiretroviral therapy. J Clin Oncol 19 (2001) 2171-2178
30. Bower M., Powles T., and Nelson M. HIV-related lung cancer in the era of highly active antiretroviral therapy. AIDS 17 (2003) 371-375
31. Antoniou T., and Tseng A.L. Interactions between antiretrovirals and antineoplastic drug therapy. Clin Pharmacokinet 44 (2005) 111-145
32. Kivisto K.T., Kroemer H.K., and Eichelbaum M. The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: implications for drug interactions. Br J Clin Pharmacol 40 (1995) 523-530
33. Moyle G.J., Gazzard B.G., and Cooper D.A. Antiretroviral therapy for HIV infection. A knowledge-based approach to drug selection and use. Drugs 55 (1998) 383-404
34. Kelly K., Crowley J., and Bunn Jr. P.A. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol 19 (2001) 3210-3218
35. Scagliotti G.V., De Marinis F., and Rinaldi M. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol 20 (2002) 4285-4291
36. Spira A., and Ettinger D.S. Multidisciplinary management of lung cancer. N Engl J Med 350 (2004) 379-392
37. Bertz R.J., and Granneman G.R. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin Pharmacokinet 32 (1997) 210-258
38. Bardelmeijer H.A., Ouwehand M., and Buckle T. Low systemic exposure of oral docetaxel in mice resulting from extensive first-pass metabolism is boosted by ritonavir. Cancer Res 62 (2002) 6158-6164
39. Bohme A., Ganser A., and Hoelzer D. Aggravation of vincristine-induced neurotoxicity by itraconazole in the treatment of adult ALL. Ann Hematol 71 (1995) 311-312
40. Bundow D., and Aboulafia D.M. Potential drug interaction with paclitaxel and highly active antiretroviral therapy in two patients with AIDS-associated Kaposi sarcoma. Am J Clin Oncol 27 (2004) 81-84
41. Engels F.K., Ten Tije A.J., and Baker S.D. Effect of cytochrome P450 3A4 inhibition on the pharmacokinetics of docetaxel. Clin Pharmacol Ther 75 (2004) 448-454
42. Royer I., Monsarrat B., and Sonnier M. Metabolism of docetaxel by human cytochromes P450: interactions with paclitaxel and other antineoplastic drugs. Cancer Res 56 (1996) 58-65
43. Schwartz J.D., Howard W., and Scadden D.T. Potential interaction of antiretroviral therapy with paclitaxel in patients with AIDS-related Kaposi's sarcoma. AIDS 13 (1999) 283-284